

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS	3	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS	4	Oct 09	Number of Derwent World Patents Index updates increased
NEWS	5	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS	6	Oct 22	Over 1 million reactions added to CASREACT
NEWS	7	Oct 22	DGENE GETSIM has been improved
NEWS	8	Oct 29	AAASD no longer available
NEWS	9	Nov 19	New Search Capabilities USPATFULL and USPAT2
NEWS	10	Nov 19	TOXCENTER(SM) - new toxicology file now available on STN
NEWS	11	Nov 29	COPPERLIT now available on STN
NEWS	12	Nov 29	DWPI revisions to NTIS and US Provisional Numbers
NEWS	13	Nov 30	Files VETU and VETB to have open access
NEWS	14	Dec 10	WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS	15	Dec 10	DGENE BLAST Homology Search
NEWS	16	Dec 17	WELDASEARCH now available on STN
NEWS	17	Dec 17	STANDARDS now available on STN
NEWS	18	Dec 17	New fields for DPCI
NEWS	19	Dec 19	CAS Roles modified
NEWS	20	Dec 19	1907-1946 data and page images added to CA and Cplus
NEWS	21	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS	22	Jan 25	Searching with the P indicator for Preparations
NEWS	23	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS	24	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS EXPRESS			February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:03:05 ON 15 FEB 2002

=> file medline, uspatful, dgene, embase, biosis

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'MEDLINE' ENTERED AT 11:03:21 ON 15 FEB 2002

FILE 'USPATFULL' ENTERED AT 11:03:21 ON 15 FEB 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 11:03:21 ON 15 FEB 2002  
COPYRIGHT (C) 2002 DERWENT INFORMATION LTD

FILE 'EMBASE' ENTERED AT 11:03:21 ON 15 FEB 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:03:21 ON 15 FEB 2002  
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

=> s coronary artery disease

L1 109645 CORONARY ARTERY DISEASE

=> s l1 and treatment

L2 20920 L1 AND TREATMENT

=> s fibroblast growth factor

L3 55916 FIBROBLAST GROWTH FACTOR

=> s l3 and l2

L4 234 L3 AND L2

=> s (fibroblast growth factor-2)

L5 4357 (FIBROBLAST GROWTH FACTOR-2)

=> s l5 and l2

L6 7 L5 AND L2

=> d l6 ti abs ibib tot

L6 ANSWER 1 OF 7 USPATFULL

TI Artery - and vein-specific proteins and uses therefor

AB Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts

the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:165440 USPATFULL

TITLE: Artery - and vein-specific proteins and uses therefor

INVENTOR(S): Wang, Hai U., Pasadena, CA, United States

Chen, Zhoufeng, Pasadena, CA, United States

Anderson, David J., Altadena, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001024650	A1	20010927
APPLICATION INFO.:	US 2001-823009	A1	20010330 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-85820, filed on 28 May 1998, PENDING Continuation-in-part of Ser. No. US 1998-83546, filed on 22 May 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-81757	19980413 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	David E. Brook, Esq., HAMILTON, BROOK, SMITH & REYNOLDS, P.C., Two Militia Drive, Lexington, MA, 02421-4799	
NUMBER OF CLAIMS:	108	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	1613	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 7 USPATFULL

TI Platelet derived growth factor (PDGF) nucleic acid ligand complexes

AB This invention discloses a method for preparing a complex comprised of a

PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid

Ligand

with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid

Ligand

or Complex and methods for making the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:67813 USPATFULL

TITLE: Platelet derived growth factor (PDGF) nucleic acid ligand complexes

INVENTOR(S): Janjic, Nebojsa, Boulder, CO, United States

Gold, Larry, Boulder, CO, United States

PATENT ASSIGNEE(S): NeXstar Pharmaceuticlas, Inc., Boulder, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6229002	B1	20010508
APPLICATION INFO.:	US 1997-991743		19971216 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-618693, filed on 20 Mar 1996, now patented, Pat. No. US 5723594		
	Continuation-in-part of Ser. No. US 1995-479783, filed on 7 Jun 1995, now patented, Pat. No. US 5668264		
	Continuation-in-part of Ser. No. US 1995-479725, filed on 7 Jun 1995, now patented, Pat. No. US 5674685		

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Zitomer, Stephanie  
LEGAL REPRESENTATIVE: Swanson & Bratschun LLC  
NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 30 Drawing Figure(s); 26 Drawing Page(s)  
LINE COUNT: 3002  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
TI Vascular growth factor and gene therapy to induce new vessels in the ischemic myocardium.  
AB In summary, angiogenic vascular endothelial growth factor therapy either with the protein itself or with the gene encoding for the vascular growth factor is a new promising potential therapeutic alternative to patients with severe **coronary artery disease**, which cannot be treated with conventional revascularization with PTCA or CABG. The **treatment** regimes evaluated seem to be safe. However, we have to await the results of ongoing and future larger scale double-blind placebo-controlled studies of genes encoding for the vascular growth factors or of the protein formulations before we can define the role of vascular growth factor **treatment** in ischemic heart disease.

ACCESSION NUMBER: 2002042919 EMBASE  
TITLE: Vascular growth factor and gene therapy to induce new vessels in the ischemic myocardium.  
AUTHOR: Kastrup J.; Jorgensen E.; Drvota V.  
CORPORATE SOURCE: Dr. J. Kastrup, Medical Department B, The Heart Centre, University Hospital, DK-2100 Copenhagen O, Denmark.  
jkastrup@rh.dk  
SOURCE: Scandinavian Cardiovascular Journal, (2001) 35/5  
(291-296).  
Refs: 27  
ISSN: 1401-7431 CODEN: SCJOFY  
COUNTRY: Norway  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery  
022 Human Genetics  
) 030 Pharmacology  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L6 ANSWER 4 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
TI Therapeutic angiogenesis for **coronary artery disease**.  
AB A large body of evidence in animal models of ischemia shows that administration of angiogenic growth factors, either as recombinant protein or by gene transfer, can augment nutrient perfusion through neovascularization. Many cytokines have angiogenic activity; those that have been best studied in animal models and clinical trials are vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). Clinical trials of therapeutic angiogenesis in patients with end-stage **coronary artery disease** have shown increases in exercise time and reductions in anginal symptoms and have provided objective evidence of improved perfusion and left ventricular function. Larger-scale placebo-controlled trials have been limited to intracoronary and intravenous administration of recombinant protein and have not yet shown significant improvement in exercise time or angina compared with placebo. Larger-scale placebo-controlled studies of gene transfer are in progress. Clinical studies are required to determine the optimal dose, formulation, route of administration, and combinations of growth factors and the utility of adjunctive endothelial progenitor-cell or stem-cell

supplementation, to provide safe and effective therapeutic myocardial angiogenesis. Determination of which growth factors or cells are required to optimize therapeutic neovascularization in an individual patient should be a goal of future research.

ACCESSION NUMBER: 2002017430 EMBASE

TITLE: Therapeutic angiogenesis for **coronary artery disease.**

AUTHOR: Freedman S.B.; Isner J.M.; Neely M.

CORPORATE SOURCE: M. Neely, St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA 02135, United States. mneely222@aol.com

SOURCE: Annals of Internal Medicine, (1 Jan 2002) 136/1 (54-71).

Refs: 165

ISSN: 0003-4819 CODEN: AIMEAS

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 004 Microbiology

006 Internal Medicine

018 Cardiovascular Diseases and Cardiovascular Surgery

023 Nuclear Medicine

037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

L6 ANSWER 5 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

TI Surgical and percutaneous myocardial angiogenesis induction. Part II - Neoangiogenesis.

AB Coronary artery bypass surgery and angioplasty provide symptomatic relief in patients with ischemic heart disease, but despite advancement in technique and devices, these methods are not applicable to a subset of patients with angina refractory to medical **treatment**. Bypass surgery might not be feasible because of lack of suitable conduits, diffuse coronary disease or poor distal run-off, and coronary angioplasty is sometimes not applicable due to chronic total occlusion, diffuse disease or extreme tortuosity. We have previously reviewed the available experience with laser-induced direct myocardial revascularization, one of the new potential **treatment** modalities for this patient subset. One of the potential mechanisms of action for laser **treatment** is the induction of neoangiogenesis. In the second part of our article we review the available experience with the induction of myocardial angiogenesis using different growth factors or the genes encoding for them.

ACCESSION NUMBER: 2001080439 EMBASE

TITLE: Surgical and percutaneous myocardial angiogenesis induction. Part II - Neoangiogenesis.

AUTHOR: Gimelli G.; Di Mario C.; Liistro F.; Dharmadhikari A.V.; Montorfano M.; Anzuini A.; Vaghetti M.; Puchala-Borowik

M.; Airoldi F.; Carlino M.; Tzifos V.; Maisano F.; Alfieri O.; Colombo A.

CORPORATE SOURCE: Dr. C. Di Mario, Cardiologia Interventistica, Ospedale San Raffaele, Via Olgettina 60, 20132 Milano, Italy. segreteria.emodinamica@hsr.it

SOURCE: Italian Heart Journal, (2001) 2/1 (21-24).

Refs: 30

ISSN: 1129-471X CODEN: IHJOAM

COUNTRY: Italy

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery

022 Human Genetics

030 Pharmacology

037 Drug Literature Index

038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

L6 ANSWER 6 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

TI Angiogenesis in cardiovascular disease. Current status and therapeutic potential.

AB Therapeutic angiogenesis, in the form of growth factor protein administration or gene therapy, has emerged as a new method of **treatment** for patients with severe, inoperable **coronary artery disease**. Improved myocardial perfusion and function after the administration of angiogenic growth factors has been demonstrated in animal models of chronic myocardial ischaemia. Recently, preliminary clinical trials using growth factor proteins or genes encoding these angiogenic factors have demonstrated clinical and other objective evidence of relevant angiogenesis. Thus, therapeutic angiogenesis has the potential to extend **treatment** options to patients who are not optimal candidates for conventional methods of myocardial revascularisation.

ACCESSION NUMBER: 1999318613 EMBASE

TITLE: Angiogenesis in cardiovascular disease. Current status and therapeutic potential.

AUTHOR: Sellke F.W.; Simons M.

CORPORATE SOURCE: Dr. F.W. Sellke, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, United States. fsellke@bidmc.harvard.edu

SOURCE: Drugs, (1999) 58/3 (391-396).

Refs: 34

ISSN: 0012-6667 CODEN: DRUGAY

COUNTRY: New Zealand

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery  
030 Pharmacology  
037 Drug Literature Index  
039 Pharmacy

LANGUAGE: English

SUMMARY LANGUAGE: English

L6 ANSWER 7 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

TI Fibroblast growth factor-mediated angiogenesis for the **treatment** of ischemia. Lessons learned from experimental models and early human experience.

AB Fibroblast growth factors (FGFs) are a family of nearly twenty heparin-binding growth factors. They are widely distributed throughout the body, but their activity is tightly controlled. This review will focus on fibroblast growth factor-1 /FGF-1) and **fibroblast growth factor-2** (FGF-2) which have been studied extensively in vitro and in vivo. These two growth factors stimulate the proliferation of

cells of mesenchymal origin, including the three principal vascular cell types: fibroblasts, endothelial cells and smooth muscle cells. The molecular characteristics of these growth factors, their receptors, distribution, function, pharmacokinetics, hemodynamic effects and toxicity

are reviewed herein. The experimental evidence for the potential for FGFs as therapeutic agents for the **treatment** of progressive myocardial ischemia, acute myocardial ischemia, and peripheral limb ischemia is also analyzed. It is not known to what extent the results of animal studies can be extrapolated to humans with ischemic cardiovascular disease. Clinical trials have been initiated, and there is a growing hope that the pharmacologic use of growth factors will represent a viable therapeutic alternative for patients with ischemic cardiovascular disease.

ACCESSION NUMBER: 1998372756 EMBASE

TITLE: Fibroblast growth factor-mediated angiogenesis for the  
treatment of ischemia. Lessons learned from  
experimental models and early human experience.  
AUTHOR: Goncalves L.M.  
CORPORATE SOURCE: L.M. Goncalves, Cardiology Branch, National Heart,  
Lung/Blood Institute, National Institutes of Health, 10  
Center Drive, Bethesda, MD 20892-1518, United States.  
goncalvl@gwgate.nhlbi.nih.gov  
SOURCE: Revista Portuguesa de Cardiologia, (1998) 17/SUPPL. 2  
(11-20).  
Refs: 103  
ISSN: 0304-4750 CODEN: RPCADZ  
COUNTRY: Portugal  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery  
030 Pharmacology  
037 Drug Literature Index  
052 Toxicology  
LANGUAGE: English  
SUMMARY LANGUAGE: English; Portuguese